Investors / Switzerland / Novartis Venture Fund
Novartis Venture Fund
Corporate VC · Switzerland · Europe
Novartis Venture Fund is a life science venture fund managing approximately USD 750 million in committed capital with more than 40 portfolio companies. It makes equity investments in biotechnology and biopharmaceutical companies and takes board seats to work closely with management.
Invests inHealthcare & Biotech
In its own wordsbiotechbiopharmatherapeuticslife sciencesdrug development
Your fit with Novartis Venture Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNovartis Venture Fund lists 31 checked portfolio companies on its own site and is named in 11 funding rounds, 3 of them as lead. Its most frequent entry is Series B, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 30% of its companies are based in United States. It invests most often alongside Brandon Capital, Omega Funds and Ysios Capital.
Counts come from funding rounds that name Novartis Venture Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Novartis Venture Fund's whole history. Rounds on record name 10 companies; its own site lists 31. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 20% |
| Series B | 50% |
| Growth | 30% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 6 | 1 |
| '26 | 5 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 69th | 31 companies |
| Recent activity | 91th | 7 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 91th | 19% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 91th | 8 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Brandon Capital | 4 |
| Omega Funds | 4 |
| Ysios Capital | 4 |
| BioGeneration Ventures | 3 |
| Brandon BioCatalyst | 3 |
| 3B Future Health Fund | 2 |
| Agent Capital | 2 |
| Casdin Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2994%
- No longer answers00%
- Points to another company26%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Novartis Venture Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Novartis Venture Fund| Date | Company | Stage |
|---|---|---|
| 19 Aug 2026 | Series A Led | |
| 7 Jul 2026 | Series C+ | |
| 30 Jun 2026 | Series C+ | |
| 8 Jan 2026 | Series B | |
| 18 Dec 2025 | Series A | |
| 1 Dec 2025 | Series B Led | |
| 8 Sept 2025 | Series B | |
| 4 Sept 2025 | Series C+ |
Round details for Novartis Venture Fund
Amounts, full round histories and every co-investor in Novartis Venture Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
31 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Amphista Therapeutics is developing drugs to bring life-changing medicines to patients | Healthcare & Biotech | Portfolio page | ||
| Anaveon develops next-generation biologics designed to selectively eliminate or reprogram pathogenic immune cells in autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Aravax is dedicated to developing next-generation immunotherapies for the treatment of food allergy | Healthcare & Biotech | Portfolio page | ||
| The company is developing new therapies that address core problems in abnormal heart rhythms. | Healthcare & Biotech | Portfolio page | ||
| AstronauTx develops therapeutics to treat neurological disorders by improving sleep architecture | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Averna Therapeutics is developing technology to safely and effectively deliver and durably integrate large sets of genetic instructions | Healthcare & Biotech | Portfolio page | ||
| CatalYm is developing a safe and efficacious immune therapy for solid tumors. | Healthcare & Biotech | Portfolio page | ||
| Citryll develops therapies to treat immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs) | Healthcare & Biotech | Portfolio page | ||
| Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. | Healthcare & Biotech | Portfolio page | ||
| EpiBiologics develops medicines that use bispecific antibodies to selectively degrade disease-causing extracellular proteins | Healthcare & Biotech | Jan 2026Series B | Page + round | |
| Epsilogen is a company that discovers and develops immunoglobulin IgE, IgA and IgG-based therapeutics for the treatment of cancer | Healthcare & Biotech | Portfolio page | ||
| Flare Therapeutics designs small molecules to treat disease, particularly cancer, by regaining transcriptional control hijacked by cancer cells. | Healthcare & Biotech | Jun 2026Series C+ | Funding round | |
| Fore Biotherapeutics develops targeted therapies for treating cancers. | Healthcare & Biotech | May 2025Series C+ · 2 rounds | Page + round | |
| FoRx Therapeutics is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting DNA Replication Stress in treatment-resistant cancers. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Dec 2025Series A | Funding round | ||
| GentiBio is a clinical-stage company developing engineered Treg therapies to cure Type 1 diabetes and other autoimmune or acute inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| Granite Bio is a biotechnology company developing first-in-class antibodies for therapeutic use | Healthcare & Biotech | Portfolio page | ||
| Hyku Biosciences is developing small molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression. | Healthcare & Biotech | Portfolio page | ||
| Aug 2026Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- nvfund.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 22 May 2025
- Companies checked
- 31
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Novartis Venture Fund's profile as data
Pull Novartis Venture Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/nvfund.com
# also
GET /v1/firms/nvfund.com/portfolio
GET /v1/firms/nvfund.com/coinvestors
GET /v1/firms/nvfund.com/news